Research Article
BibTex RIS Cite

The relationship between polypharmacy and quality of life in kidney transplant patients

Year 2024, Volume: 41 Issue: 3, 641 - 645, 30.09.2024

Abstract

Chronic kidney disease (CKD) is becoming more widespread globally. Thanks to renal replacement therapy (RRT) methods, the life expectancy of CKD patients is gradually increasing. Today, the notion of quality of life has come to the forefront in evaluating treatment efficacy with increasing life expectancy. Among the RRT methods, kidney transplantation is the one that improves the quality of life the most. Polypharmacy is a concept that has been on the agenda recently and is known to have adverse effects on quality of life. Kidney transplant patients are frequently exposed to polypharmacy due to immunosuppressive drugs and comorbidities, particularly during the initial stages of transplantation. In our study, the KDQOL-SF questionnaire was administered to 128 kidney transplant recipients who visited the Nephrology outpatient clinic between October 2023 and November 2023. Those taking ≥6 medications were defined as the group exposed to polypharmacy. Polypharmacy was considered present in 74 of the patients involved in the study. The mean age of the patients was 51.8 ±11.5 years in the polypharmacy group and 42.4 ±12.5 years in the non-polypharmacy group. In renal transplant patients, the quality of life was notably reduced in the polypharmacy group. The presence of polypharmacy showed a statistically significant correlation with age, comorbidity, multimorbidity, marital status, and primary disease. The group with polypharmacy had notably lower scores in all sub-parameters of the KDQOL-SF. In conclusion, our study determined that the presence of polypharmacy had a negative impact on the quality of life of renal transplant patients. Polypharmacy was found to be associated with age, comorbidity and multimorbidity.

References

  • Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The lancet. 2020;395(10225):709-33.
  • Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, et al. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) conference. Clinical Journal of the American Society of Nephrology. 2008;3(2):471-80.
  • Hardinger KL, Hutcherson T, Preston D, Murillo D. Influence of pill burden and drug cost on renal function after transplantation. Pharmacotherapy. 2012;32(5):427-32.
  • Moradi O, Karimzadeh I, Davani-Davari D, Shafiekhani M, Sagheb MM, Raees-Jalali GA. Drug-Drug Interactions among Kidney Transplant Recipients in The Outpatient Setting. Int J Organ Transplant Med. 2020;11(4):185-95.
  • Vlaminck H, Maes B, Evers G, Verbeke G, Lerut E, Van Damme B, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant. 2004;4(9):1509-13.
  • Wozniak I, Kolonko A, Chudek J, Nowak L, Farnik M, Wiecek A. Influence of Polypharmacy on the Quality of Life in Stable Kidney Transplant Recipients. Transplant Proc. 2018;50(6):1896-9.
  • Long PH. On the quantity and quality of life. Med Times. 1960;88:613-9.
  • Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Annals of internal medicine. 1993;118(8):622-9.
  • Henderson JA, Buchwald D, Manson SM. Relationship of medication use to health-related quality of life among a group of older American Indians. Journal of applied gerontology. 2006;25(1_suppl):89S-104S.
  • Schmidt IM, Hübner S, Nadal J, Titze S, Schmid M, Bärthlein B, et al. Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study. Clinical kidney journal. 2019;12(5):663-72.
  • Balkhi B, AlQahtani N, Alwhaibi M, Alshammari TM, Alhawassi TM, Mahmoud MA, et al. Prevalence and factors associated with polypharmacy use among adult patients in Saudi Arabia. Journal of Patient Safety. 2021;17(8):e1119-e24.
  • Adhikari UR, Taraphder A, Hazra A, Das T. Pill burden does not influence compliance with oral medication in recipients of renal transplant. Indian journal of pharmacology. 2016;48(1):21-5.
  • Al Ameri MN, Makramalla E, Albur U, Kumar A, Rao P. Prevalence of polypharmacy in the elderly: Implications of age, gender, comorbidities and drug interactions. J Pharm Pharm Sci. 2014;1:1-7.
  • Adjeroh L, Brothers T, Shawwa K, Ikram M, Al-Mamun MA. The association between polypharmacy and health-related quality of life among non-dialysis chronic kidney disease patients. Plos one. 2023;18(11):e0293912.
Year 2024, Volume: 41 Issue: 3, 641 - 645, 30.09.2024

Abstract

References

  • Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The lancet. 2020;395(10225):709-33.
  • Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, et al. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) conference. Clinical Journal of the American Society of Nephrology. 2008;3(2):471-80.
  • Hardinger KL, Hutcherson T, Preston D, Murillo D. Influence of pill burden and drug cost on renal function after transplantation. Pharmacotherapy. 2012;32(5):427-32.
  • Moradi O, Karimzadeh I, Davani-Davari D, Shafiekhani M, Sagheb MM, Raees-Jalali GA. Drug-Drug Interactions among Kidney Transplant Recipients in The Outpatient Setting. Int J Organ Transplant Med. 2020;11(4):185-95.
  • Vlaminck H, Maes B, Evers G, Verbeke G, Lerut E, Van Damme B, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant. 2004;4(9):1509-13.
  • Wozniak I, Kolonko A, Chudek J, Nowak L, Farnik M, Wiecek A. Influence of Polypharmacy on the Quality of Life in Stable Kidney Transplant Recipients. Transplant Proc. 2018;50(6):1896-9.
  • Long PH. On the quantity and quality of life. Med Times. 1960;88:613-9.
  • Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Annals of internal medicine. 1993;118(8):622-9.
  • Henderson JA, Buchwald D, Manson SM. Relationship of medication use to health-related quality of life among a group of older American Indians. Journal of applied gerontology. 2006;25(1_suppl):89S-104S.
  • Schmidt IM, Hübner S, Nadal J, Titze S, Schmid M, Bärthlein B, et al. Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study. Clinical kidney journal. 2019;12(5):663-72.
  • Balkhi B, AlQahtani N, Alwhaibi M, Alshammari TM, Alhawassi TM, Mahmoud MA, et al. Prevalence and factors associated with polypharmacy use among adult patients in Saudi Arabia. Journal of Patient Safety. 2021;17(8):e1119-e24.
  • Adhikari UR, Taraphder A, Hazra A, Das T. Pill burden does not influence compliance with oral medication in recipients of renal transplant. Indian journal of pharmacology. 2016;48(1):21-5.
  • Al Ameri MN, Makramalla E, Albur U, Kumar A, Rao P. Prevalence of polypharmacy in the elderly: Implications of age, gender, comorbidities and drug interactions. J Pharm Pharm Sci. 2014;1:1-7.
  • Adjeroh L, Brothers T, Shawwa K, Ikram M, Al-Mamun MA. The association between polypharmacy and health-related quality of life among non-dialysis chronic kidney disease patients. Plos one. 2023;18(11):e0293912.
There are 14 citations in total.

Details

Primary Language English
Subjects Nefroloji
Journal Section Research Article
Authors

Furkan Çakmak 0000-0002-0990-7640

Ahmet Karataş 0000-0001-9095-6054

Ercan Türkmen 0000-0001-5445-4735

Nurol Arık 0000-0001-5278-5207

Publication Date September 30, 2024
Submission Date March 29, 2024
Acceptance Date September 16, 2024
Published in Issue Year 2024 Volume: 41 Issue: 3

Cite

APA Çakmak, F., Karataş, A., Türkmen, E., Arık, N. (2024). The relationship between polypharmacy and quality of life in kidney transplant patients. Journal of Experimental and Clinical Medicine, 41(3), 641-645.
AMA Çakmak F, Karataş A, Türkmen E, Arık N. The relationship between polypharmacy and quality of life in kidney transplant patients. J. Exp. Clin. Med. September 2024;41(3):641-645.
Chicago Çakmak, Furkan, Ahmet Karataş, Ercan Türkmen, and Nurol Arık. “The Relationship Between Polypharmacy and Quality of Life in Kidney Transplant Patients”. Journal of Experimental and Clinical Medicine 41, no. 3 (September 2024): 641-45.
EndNote Çakmak F, Karataş A, Türkmen E, Arık N (September 1, 2024) The relationship between polypharmacy and quality of life in kidney transplant patients. Journal of Experimental and Clinical Medicine 41 3 641–645.
IEEE F. Çakmak, A. Karataş, E. Türkmen, and N. Arık, “The relationship between polypharmacy and quality of life in kidney transplant patients”, J. Exp. Clin. Med., vol. 41, no. 3, pp. 641–645, 2024.
ISNAD Çakmak, Furkan et al. “The Relationship Between Polypharmacy and Quality of Life in Kidney Transplant Patients”. Journal of Experimental and Clinical Medicine 41/3 (September 2024), 641-645.
JAMA Çakmak F, Karataş A, Türkmen E, Arık N. The relationship between polypharmacy and quality of life in kidney transplant patients. J. Exp. Clin. Med. 2024;41:641–645.
MLA Çakmak, Furkan et al. “The Relationship Between Polypharmacy and Quality of Life in Kidney Transplant Patients”. Journal of Experimental and Clinical Medicine, vol. 41, no. 3, 2024, pp. 641-5.
Vancouver Çakmak F, Karataş A, Türkmen E, Arık N. The relationship between polypharmacy and quality of life in kidney transplant patients. J. Exp. Clin. Med. 2024;41(3):641-5.